Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has provoked considerable interest over recent years as a novel therapeutic target in cancer. A brief outline of the IGF-1R signalling system and the rationale for its use in cancer medicine is given. This is followed by a discussion of the different possible targets within the IGF-1R system, and drugs developed to interact at each target. A systems-based approach is then used to review the in vitro and in vivo data in the published literature of the following compounds targeting IGF-1R components using specific examples: growth hormone releasing hormone antagonists (e.g. JV-1-38), growth hormone receptor antagonists (e.g. pegvisomant), IGF-1R antibodies (e.g. CP-751,871, AVE1642/EM164, IMC-A12, SCH-717454, BIIB022, AMG 479, MK-0646/h7C10), and IGF-1R tyrosine kinase inhibitors (e.g. BMS-536942, BMS-554417, NVP-AEW541, NVP-ADW742, AG1024, potent quinolinyl-derived imidazo (1,5-a)pyrazine PQIP, picropodophyllin PPP, Nordihydroguaiaretic acid Insm-18/NDGA). The following tumour types are specifically discussed: lung, breast, colorectal, pancreatic, NETs, sarcoma, prostate, leukaemia, multiple myeloma. Other tumour types are mentioned briefly: squamous cell carcinoma of the head and neck, melanoma, glioblastoma, ovary, gastric and mesothelioma. Results of early stage clinical trials, involving recently patented drugs. are included where appropriate. We then outline the current understanding of toxicity related to IGF-1R targeted therapy, and finally outline areas for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le Bouc, Y. (2003) · Nature · doi:10.1038/nature01298 · Cited by 2,109 · cited 1×
“The IGF-1R system also affects tumour cell motility, cellular density and hypoxic response [34-40].”
BackgroundRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“The Ras/Raf and PI3K pathways then converge at the mammalian target of rapamycin, mTOR, which again can cause effects on cell growth [33, 47, 48].”
BackgroundNahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245 · cited 1×
“001) [87].”
Cited by
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Rajski, M., Zanetti-Dällenbach, R., Vogel, B., Herrmann, R., Rochlitz, C., & Buess, M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-1 · Cited by 355
“Many other inhibitors of IGF signalling, applying different approaches [67], are currently under clinical investigation in phase I and II trials (reviewed in [29,70]).”
Mulvihill, M. J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., et al. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.89 · Cited by 311
Atamaniuk, J., Gleiss, A., Porpaczy, E., Kainz, B., Grunt, T. W., Raderer, M., Hilgarth, B., Drach, J., Ludwig, H., Gisslinger, H., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02679.x · Cited by 128
Targeting of the protein interaction site between FAK and IGF-1R
Zheng, D., Kurenova, E., Ucar, D., Golubovskaya, V., Magis, A., Ostrov, D., Cance, W. G., & Hochwald, S. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.156 · Cited by 30
Metadata
- Authors
- Hewish, M., Chau, I., & Cunningham, D.
- Venue
- Recent Patents on Anti-Cancer Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 4
- Issue
- 1
- Pages
- 54-72
- ISSN
- 1574-8928 (ISSN-L)
- OpenAlex
- W2115147895
- Cited by
- 141
- References
- 5
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. https://app.cochat.ai/papers/10.2174/157489209787002515
- The paper
- Hewish, M., Chau, I., & Cunningham, D. (2009). Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. Recent Patents on Anti-Cancer Drug Discovery. https://doi.org/10.2174/157489209787002515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.